Literature DB >> 17712035

Aging and Down syndrome: implications for physical therapy.

Robert C Barnhart1, Barbara Connolly.   

Abstract

The number of people over the age of 60 years with lifelong developmental delays is predicted to double by 2030. Down syndrome (DS) is the most frequent chromosomal cause of developmental delays. As the life expectancy of people with DS increases, changes in body function and structure secondary to aging have the potential to lead to activity limitations and participation restrictions for this population. The purpose of this update is to: (1) provide an overview of the common body function and structure changes that occur in adults with DS as they age (thyroid dysfunction, cardiovascular disorders, obesity, musculoskeletal disorders, Alzheimer disease, depression) and (2) apply current research on exercise to the prevention of activity limitations and participation restrictions. As individuals with DS age, a shift in emphasis from disability prevention to the prevention of conditions that lead to activity and participation limitations must occur. Exercise programs appear to have potential to positively affect the overall health of adults with DS, thereby increasing the quality of life and years of healthy life for these individuals.

Entities:  

Mesh:

Year:  2007        PMID: 17712035     DOI: 10.2522/ptj.20060334

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  15 in total

1.  Gait patterns in Prader-Willi and Down syndrome patients.

Authors:  Veronica Cimolin; Manuela Galli; Graziano Grugni; Luca Vismara; Giorgio Albertini; Chiara Rigoldi; Paolo Capodaglio
Journal:  J Neuroeng Rehabil       Date:  2010-06-21       Impact factor: 4.262

2.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

3.  Complexity of force output during static exercise in individuals with Down syndrome.

Authors:  Kevin S Heffernan; Jacob J Sosnoff; Edward Ofori; Sae Young Jae; Tracy Baynard; Scott R Collier; Stella Goulopoulou; Arturo Figueroa; Jeffrey A Woods; Kenneth H Pitetti; Bo Fernhall
Journal:  J Appl Physiol (1985)       Date:  2009-01-22

4.  The exercise redox paradigm in the Down's syndrome: improvements in motor function and increases in blood oxidative status in young adults.

Authors:  Aderbal S Aguiar; Talita Tuon; Mirella M Albuquerque; Gláucia S Rocha; Ana E Speck; Júlio C Araújo; Alcir L Dafré; Rui D S Prediger; Ricardo A Pinho
Journal:  J Neural Transm (Vienna)       Date:  2008-09-16       Impact factor: 3.575

5.  Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

Authors:  Irushi Abeysekera; Jared Thomas; Taxiarchis M Georgiadis; Alycia G Berman; Max A Hammond; Karl J Dria; Joseph M Wallace; Randall J Roper
Journal:  Mol Nutr Food Res       Date:  2016-02-11       Impact factor: 5.914

Review 6.  Skeletal dynamics of Down syndrome: A developing perspective.

Authors:  Jonathan M LaCombe; Randall J Roper
Journal:  Bone       Date:  2019-12-27       Impact factor: 4.398

7.  Adults with Down syndrome have reduced cardiac response after light exercise testing.

Authors:  J C Vis; H A C M De Bruin-Bon; B J Bouma; S A Huisman; L Imschoot; K van den Brink; B J M Mulder
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

Review 8.  Current Analysis of Skeletal Phenotypes in Down Syndrome.

Authors:  Jared R Thomas; Randall J Roper
Journal:  Curr Osteoporos Rep       Date:  2021-04-08       Impact factor: 5.163

9.  Risk of Major Cardiovascular Events in People with Down Syndrome.

Authors:  Christopher G Sobey; Courtney P Judkins; Vijaya Sundararajan; Thanh G Phan; Grant R Drummond; Velandai K Srikanth
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

10.  Resting energy expenditure and adiposity accretion among children with Down syndrome: a 3-year prospective study.

Authors:  D L Hill; E P Parks; B S Zemel; J Shults; V A Stallings; N Stettler
Journal:  Eur J Clin Nutr       Date:  2013-07-31       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.